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Abstract
Background Inappropriate drug use (IDU) is an important
risk factor for adverse outcomes in older persons. We
aimed to investigate IDU and the risk of hospitalizations
and mortality in older persons and in persons with
dementia and to estimate the costs of IDU-related
hospitalizations.
Methods We analyzed 4108 individuals aged C60 years
from the Swedish National Study on Aging and Care
(SNAC) data from Kungsholmen and Nordanstig
(2001–2004). IDU was assessed by indicators developed by
the Swedish National Board of Health and Welfare.
Hospitalizations and mortality data were collected from
Swedish registers. Regression models were used to inves-
tigate associations between IDU, hospitalizations, and
mortality in the whole population and in the subpopulation
of persons with dementia (n = 319), after adjustment for
sociodemographics, physical functioning, and co-morbid-
ity. Costs for hospitalizations were derived from the Nord-
Diagnose Related Group cost database.
Results IDU was associated with a higher risk of hospi-
talization [adjusted odds ratio (OR) = 1.46; 95 % confi-
dence interval (CI) 1.18–1.81] and mortality [adjusted
hazard ratio (HR) = 1.15; 95 % CI 1.01–1.31] within
1 year in the whole study population and with hospital-
ization (adjusted OR = 1.88; 95 % CI 1.03–3.43) in the
subpopulation of persons with dementia, after adjustment
for confounding factors. There was also a tendency for
higher costs for hospitalizations with IDU than without
IDU, although this was not statistically significant.
Conclusions Our findings suggest that IDU is associated
with an increased risk of hospitalization in older persons
and in persons with dementia. IDU is also associated with
mortality among older persons. These findings highlight
the need for cautious prescribing of long-acting benzodi-
azepines, anticholinergic drugs, concurrent use of three or
more psychotropic drugs and drug combinations that may
lead to serious drug–drug interactions to older patients.
Further studies are needed to investigate the association
between IDU and costs for hospitalizations.
Key Points
Inappropriate drug use (IDU) was associated with
hospitalization in older persons and in persons with
dementia.
IDU was also associated with mortality among older
persons.
There was a tendency for higher costs for
hospitalizations with IDU than without IDU,
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1 Introduction
The proportion of older persons is increasing worldwide
[1]. People aged 60 years and older will increase from
10 % in 2001 to more than 21 % in 2050 [1, 2]. This aging
of populations brings major challenges for healthcare sys-
tems and for societies’ resource allocation. One of these
challenges is appropriate drug prescribing to older persons.
Drug prescribing to older patients is extensive [3],
although old age is a risk factor for adverse drug reactions
[4]. Certain drug treatment that is appropriate for younger
or middle-aged patients can be inappropriate in old age due
to age-related changes in pharmacokinetics and pharma-
codynamics together with organ failure [4]. Inappropriate
drug use (IDU), e.g., long-acting benzodiazepines, anti-
cholinergic drugs, and drug combinations that may lead to
serious drug–drug interactions [5], is defined as drug
therapy that poses potential risks that outweigh potential
benefits [6]. Still, IDU is common among older persons [5]
and has been associated with health, clinical, and economic
outcomes [7]. The two most serious outcomes of IDU are
hospitalizations and mortality. We therefore focused on
these with the added value of an estimation of cost
outcomes.
Previous research about IDU and risk of hospitalizations
and mortality [8–10] has often been limited by lack of
information about important clinical variables, such as
dementia, or by analysis of small and selected samples.
Cost analysis of IDU has so far been scarce [11], although
this research is important from a stakeholder and resource
allocation perspective. Thus, we aimed to investigate IDU
and risk of hospitalizations and mortality in older persons
and in persons with dementia in a population of commu-
nity-dwelling and institutionalized individuals. We also
aimed to estimate the costs of IDU-related hospitalizations.
2 Methods
2.1 Study Population
Data for this study were obtained from the ongoing, lon-
gitudinal cohort study Swedish National Study on Aging
and Care (SNAC), which is described in detail elsewhere
[12]. In short, SNAC is a study conducted at four sites in
Sweden (Nordanstig, Kungsholmen, Karlskrona, and four
municipalities in Ska˚ne), reflecting both rural and urban
parts of Sweden. People aged 60 years and over in certain
age groups (60, 66, 72, 78, 81, 84, 87, 90, 93, 96, 99 years)
were recruited for an extensive examination, which inclu-
ded a physical examination and medical history by a
physician. Interviews covering a wide range of areas such
as socioeconomic factors, physical environment, and care
service utilization were also conducted by a nurse, and tests
of psychological status and cognitive performance were
made by a psychologist. The data used in this study were
collected at baseline during the years 2001–2004 in Nor-
danstig, a rural area in the middle of Sweden, and Kung-
sholmen, an urban area in Stockholm (n = 4129).
2.2 Sociodemographic Variables
Age was categorized into 60–69, 70–79, 80–89, and
C90 years in the descriptive analysis and used as a con-
tinuous variable in the regression models. Residential set-
ting was dichotomized into community dwelling (i.e.,
living in one’s own home) versus institution (sheltered
accommodation, old people’s home, group dwelling, or
nursing home). Educational level was classified into ele-
mentary versus additional schooling.
2.3 Drug Use
Use of drugs was recorded by the physician and the par-
ticipants were asked to bring current lists of medications,
drug containers, and prescriptions. If the participant was
not able to answer, an informant close to the person (rel-
ative or carer) was asked to provide the information. Drug
use was defined as use of a drug regularly at the time of the
interview or as needed at any time during the preceding
month. Regular use was defined as the use of a drug on a
scheduled basis (e.g., day, week, or fortnight). Data on both
prescribed drugs and over-the-counter drugs were collected
[12]. The dose and frequency of the drugs used were also
collected. Polypharmacy was defined as use of five or more
drugs regularly. Drugs were classified according to the
anatomical therapeutic and chemical (ATC) system [13].
2.4 Inappropriate Drug Use (IDU)
IDU was defined according to the indicators developed by
the Swedish National Board of Health and Welfare [5, 14,
15]: concurrent use of three or more psychotropic drugs
(from any of the groups antipsychotics, anxiolytics, hyp-
notics-sedatives, and antidepressants), use of drugs with
anticholinergic properties (urinary and gastrointestinal
antispasmodics, anticholinergic antiemetics, class Ia
antiarrhythmics, anticholinergic antiparkinsonian drugs,
low-potency antipsychotics, tricyclic antidepressants, and
first-generation antihistamines), use of long-acting benzo-
diazepines (diazepam, nitrazepam, or flunitrazepam), and
serious drug–drug interactions according to the system by
Sjo¨qvist [16]. IDU was defined as exposure to at least one
of these four indicators [5].
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2.5 Dementia
Dementia was diagnosed by physicians according to the
Diagnostic and Statistical Manual of Mental Disorders,
Third Edition, Revised (DSM-III-R) [17].
2.6 Co-Morbidity
We used the Charlson Comorbidity Index, which is often
used to adjust for confounding by co-morbidities [18]. The
version applied in this study was adapted to the availability
of data [8]. We used seven diagnoses with a weight of one
(congestive heart failure, myocardial infarction, cere-
brovascular disease, dementia, chronic pulmonary disease,
connective tissue disorder, and diabetes mellitus without
complication) and two diagnoses with a weight of two
(moderate or severe renal failure and any tumor), which
gives a maximum total of 11. The comorbidity index was
entered as a dichotomous variable in the analysis (none vs.
one or more modified Charlson Comorbidity Index
weights).
Diagnoses of diseases in the index were all based on
medical history and examination of the physician except
renal failure and dementia. Renal failure was calculated
from Cockcroft-Gault formula [19] and defined as esti-
mated creatinine clearance\25 mL/min. Dementia diag-
nosis is included in the Charlson Comorbidity Index, but
dementia was analyzed as a separate variable in the
regression analysis and was, thus, removed from the index.
2.7 Physical Functioning
Physical functioning was assessed by the Katz index of
activities of daily living (ADL) [20]. The Katz ADL is a
scale that measures functional dependency in six basic
activities: transferring, dressing, bathing, going to the toi-
let, feeding, and continence. Functional independence was
defined as no need of assistance and dependent was defined
as being dependent in one or more activities.
2.8 Hospitalizations and Mortality
Data on mortality and hospitalizations were collected from
registers at the Swedish National Board of Health and
Welfare. Both death certificates and data on hospitalization
were collected from individual entrance into the study until
1 year after the last date of inclusion in the study.
2.9 Costs of Hospitalization
Cost data of hospitalization were derived from the
Nord-Diagnose Related Group (DRG) cost database
[21]. This is a Swedish version of the original Diag-
nosis Related Group (DRG) database [22], which was
produced to rationalize cost-finding for budgeting and
visualize costing for practitioners. Each DRG code was
derived from the corresponding International Classifi-
cation of Diseases (ICD) code [23] with a specific
weight. This weight was then multiplied by the DRG
cost of weight 1 in order to calculate the total cost of
the hospitalization.
Any health economic analysis needs to have a specified
viewpoint [24]. This paper focuses on costs of hospital-
izations, which is a part of medical sector costs. Costs of
the community care sector and costs of informal care are
therefore not included. Furthermore, the only additional
outcome was mortality. No other effects, such as quality of
life or functional capacity, were included. The basic health
economic design is descriptive and there is no predefined
hypothesis regarding cost effectiveness. Thus, the health
economic approach in this paper can be regarded as a cost
description that can generate hypotheses for interventions
regarding IDU.
2.10 Statistical Analysis
Descriptive demographic statistics were made with cross-
tabulations. Logistic regression analysis was used to
investigate the association between IDU and hospitaliza-
tions within 1 year of assessment of IDU, after adjustment
for covariates. Similarly, Cox regression models were used
for analysis of IDU and mortality within 1 year of
assessment of IDU, after adjustment for covariates. The
outcomes hospitalizations and mortality were analyzed in
the whole study population and in the subpopulation of
persons with dementia. There were no significant differ-
ences in IDU between the two sites, Nordanstig and
Kungsholmen, and inclusion of site did not affect the
results of the regression models; thus, this variable was not
included in the analyses. The results are shown as odds
ratios (ORs) and hazard ratios (HRs) with 95 % confidence
intervals (95 % CIs). We used one-way analysis of vari-
ance (ANOVA) to explore differences in mean cost of
hospitalizations with and without IDU, after adjustment for
age. A p value of\0.05 was considered statistically sig-
nificant. All analysis was made with IBM SPSS Statistics
version 22 [25].
2.11 Ethics
The study was approved by the ethical review board in
Stockholm (dnr 01-114, dnr 2009/595-32) and in Uppsala
(dnr 01-123). Informed consent was obtained from all
participants included in the study.
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3 Results
The characteristics of the study participants are shown in
Table 1. Of the 4129 participants, 21 did not have infor-
mation on drug use and were therefore excluded from the
analyses (n = 4108). The mean age of the population was
74.8 years [standard deviation (SD) = 11.1; ran-
ge = 60–105 years) and 81 % used at least one drug. The
mean number of drugs used was 3.6 (SD = 3.4; range
0–23) and the proportion of persons with polypharmacy
(use of five or more drugs) was 33 %. The overall preva-
lence of IDU was 13 %; 27 % among persons with
dementia and 12 % among persons without dementia
(p\ 0001). Women were more often exposed to IDU than
men (15 vs. 10 %; p\ 0.001). The prevalence of IDU in
institutions was 34 % and among community dwellers
12 % (p\ 0.001). In people with functional dependency in
ADL, the prevalence was higher (27 %) than in people
with functional independence (11 %) (p\ 0.001).
IDU was associated with a higher risk of hospitalization
within 1 year (adjusted OR = 1.46; 95 % CI 1.18–1.81),
after adjustment for age, sex, dementia, residential setting,
educational level, physical functioning, and co-morbidity
(Table 2). Also higher age, male sex, living at home
(community dwelling), lower educational level, functional
dependence, and a higher level of co-morbidity were
associated with higher odds for hospitalization within
1 year.
IDU was also associated with an increased risk of
mortality within 1 year (adjusted HR = 1.15; 95 % CI
Table 1 Population
characteristics and prevalence
of inappropriate drug use
Characteristic Total no. of participants No. of participants with IDU Prevalence of IDU (%)
All 4108 536 13.0
Age (years; continuous)
60–69 1559 121 7.8
70–79 1127 161 14.3
80–89 872 151 17.3
C90 550 103 18.7
Sex
Men 1528 157 10.3
Women 2580 379 14.7
Educationa
Elementary 1098 143 13.0
Additional 2976 388 13.0
Residential setting
Community dwelling 3826 440 11.5
Institution 282 96 34.0
Dementiab
No 3783 445 11.8
Yes 319 87 27.3
Charlson Comorbidity Index
0 2414 230 9.5
1 747 119 15.9
2 640 106 16.6
C3 307 81 26.4
Number of drugs
0–1 1346 11 0.8
2–4 1390 119 8.6
C5 1372 406 29.6
Katz ADL
Independent 3651 404 11.3
Dependent 409 112 27.4
ADL activities of daily living, IDU inappropriate drug use
a Missing data on education for 34 persons
b Missing data on dementia status for 6 persons
c Missing data on Katz ADL for 48 persons
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1.01–1.31), after adjustment for age, sex, dementia, resi-
dential setting, educational level, physical functioning, co-
morbidity, and hospitalization within 1 year (Table 3). The
greatest risk factors for mortality were higher age, co-
morbidity, hospitalization within 1 year, male sex, and
dementia.
Among the 319 persons with dementia (Tables 4, 5),
IDU was associated with a higher risk of hospitalization
within 1 year (adjusted OR = 1.88; 95 % CI 1.03–3.43),
but not statistically significantly associated with mortality
(adjusted HR = 1.13; 95 % CI 0.87–1.47). Furthermore,
the only additionally detected statistically significant
associations among the individuals with dementia were
between living in an institution and hospitalization (ad-
justed OR = 0.26; 95 % CI 0.13–0.50) and between age
(continuous variable) and mortality (adjusted HR = 1.02;
95 % CI 1.00–1.04).
Table 6 shows the costs for hospitalization stratified by
IDU and dementia status. There was a tendency for higher
costs of hospitalizations with IDU, although it was not
statistically significant in any group.
4 Discussion
4.1 Main Findings
This study is one of few studies that have examined the
association between IDU, hospitalization, and mortality in
a population-based setting with an added estimation of the
costs of IDU.
The overall prevalence of IDU was similar to findings
from Swedish national data [26], but slightly lower that
reported in a previous study by Klarin et al. [8] based on
Nordanstig data collected in 1995–1998 and based on an
older study population. Compared to international studies,
our prevalence of IDU is within the range of previous
reports [27], although at the lower end [28, 29]. The dif-
ferences in prevalence estimates of IDU may be explained
by differences in inclusion of age groups, IDU criteria,
Table 2 Multivariate logistic regression analysis of the association
between inappropriate drug use and hospitalization within 1 year
Characteristic OR 95 % CI






















Multivariate logistic regression is adjusted for all variables in the
table; data missing for 52 persons
ADL activities of daily living, CI confidence interval, IDU inappro-
priate drug use, OR odds ratio
Table 3 Multivariate Cox proportional hazard regression analysis for
inappropriate drug use and risk of mortality within 1 year
Characteristic HR 95 % CI

























Multivariate Cox proportional hazard regression is adjusted for all
variables in the table; data missing for 52 persons
ADL activities of daily living, CI confidence interval, HR hazard ratio,
IDU inappropriate drug use
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setting, design, and sampling techniques, e.g., convenience
samples of old hospitalized patients may over-report IDU
given that these frail persons are often a particularly
exposed group [30].
We found that IDU was associated with a higher risk of
hospitalization and mortality among older persons, after
adjustment for sociodemographic, functional, and co-mor-
bidity variables. This is in line with previous research [9,
10, 28, 30, 31]. However, the previous study by Klarin
et al. [8], which was based on rural Nordanstig data,
showed an association of IDU only with hospitalizations
but not with mortality. Our study with the inclusion of the
Kungsholmen area and with a lower age limit is much
larger and hence more statistically well-powered. To our
knowledge, this is one of the first studies to show that IDU
increases the risk of hospitalizations and mortality within
the same study. IDU is an important risk factor for adverse
drug reactions [32], which in turn can lead to hospitaliza-
tions and, in the worst-case scenario, to increased mortal-
ity. Therefore, our study gives support to the growing
evidence of detrimental outcomes of inappropriate pre-
scribing to older patients and support limited use of these
drugs.
For people with dementia, IDU was associated with a
higher risk of hospitalization. However, the association
between IDU and mortality was not statistically significant,
although the effect estimate was of the same magnitude as
that of the whole study population. More studies of IDU in
dementia cohorts are needed to confirm our findings about
outcomes of IDU in this vulnerable group of persons [33].
Our study shows a higher prevalence of IDU in insti-
tutions than in the community-dwelling setting. Haasum
et al. [26] has previously shown that institutionalization
may be a risk factor for IDU. These results underline the
need for cautious prescribing in this population of frail
older persons. Female sex has also previously been related
to IDU [34], which is in line with our study.
We found a tendency for higher costs for hospitaliza-
tions with IDU than without IDU, although it was not
statistically significant. Estimation of costs of IDU is dif-
ficult and is often reported as the costs for the drugs
involved [35, 36]. In our study, the costs of IDU were
measured as costs for hospitalizations and we therefore
Table 4 Multivariate logistic regression analysis for the association
between inappropriate drug use and hospitalization within 1 year in
people with dementia
Characteristic OR 95 % CI



















Multivariate logistic regression is adjusted for all variables in the
table; data missing for 17 persons
ADL activities of daily living, CI confidence interval, IDU inappro-
priate drug use, OR odds ratio
Table 5 Multivariate Cox proportional hazard regression analysis for
inappropriate drug use and risk of mortality in people with dementia
Characteristic HR 95 % CI






















Multivariate Cox proportional hazard regression is adjusted for all
variables in the table; data missing for 17 persons
ADL activities of daily living, CI confidence interval, HR hazard ratio,
IDU inappropriate drug use
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report higher costs than previous studies. Indeed, a recent
review article concludes that hospital costs are the main
cost driver and that they are partly preventable [11].
4.2 Strengths and Limitations
The great strength of this study is the population-based
design with the possibility to adjust for many important
confounders.
IDU was assessed at baseline and not at time of hospi-
talization or death. Hence, IDU could have been introduced
or discontinued during this period. Therefore, we chose the
rather narrow time period of 1 year between IDU assess-
ment and the two outcomes in order to limit the possible
misclassification of exposure. This may both over- and
underestimate the risk of mortality.
The overall response rate in Kungsholmen was about
73 % and in Nordanstig 75 %. There was no difference in
the sex distribution between non-responders and respon-
ders in Kungsholmen, whereas there were slightly more
responders among men than women in Nordanstig.
Confounding by indication may be present in our study,
although we adjusted for physical dependence, dementia,
and co-morbidity. In the analysis of mortality, we also
adjusted for hospitalization within 1 year as a proxy for
disease severity.
A risk with self-reported drug use is recall bias, but the
advantages over pharmacy claims data include information
closer to adherence, i.e., data were based on drugs that
were actually taken, not only purchased, and that over-the-
counter drugs are included.
Another limitation was that the cost viewpoint was
restricted to hospitalization costs. There are also post-
hospitalization costs in terms of informal care and com-
munity services as well as suffering in terms of an impaired
quality of life due to IDU, which are difficult to analyze.
5 Conclusions
Our findings suggest that IDU is associated with an
increased risk of hospitalization in older persons and in
persons with dementia. IDU is also associated with mor-
tality among older persons. These findings highlight the
need for cautious prescribing of long-acting benzodi-
azepines, anticholinergic drugs, concurrent use of three or
more psychotropic drugs and drug combinations that may
lead to serious drug–drug interactions to older patients.
Further studies are needed to investigate the association
between IDU and costs for hospitalizations.
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